Baltimore, MD (Feb. 1, 2018) -– emocha, a mobile health company whose video-based technology improves medication adherence, has hired veteran healthcare analyst Thomas A. Carroll as Chief Operating Officer. In this role, Carroll will be responsible for leading emocha’s expansion into new markets. He will also provide in-depth analyses on medication adherence-related cost savings and health outcomes improvements for emocha customers.
With more than 25 years of experience in healthcare finance, Carroll previously served as Managing Director at Stifel Nicolaus, where he produced equity research and analyst reports that were widely used by institutional investors and prominent media organizations such as CNBC, Bloomberg and CNN. He also co-founded RuxtonPark Healthcare Capital and worked as a healthcare consultant at KPMG, Doctors Health System and Alexander & Alexander Consulting.
As an analyst, Carroll earned multiple research awards published by the Wall Street Journal ("Best on the Street”), Starmine (“All Star Analysts”), Fortune Magazine and Forbes. He earned a Master of Health Science degree from the Johns Hopkins Bloomberg School of Public health and a Bachelor of Science degree in finance from Towson University.
Medication nonadherence is a massive problem that leads to devastating health outcomes for patients and exorbitant costs for providers, payers, and health systems. On average, patients only take about half of their medications, which leads to more than $100 billion in costs annually. emocha's technology has been proven to help patients achieve greater than 90 percent medication adherence on a dose-by-dose basis.
“emocha is the only medication adherence technology that is immediately scalable, has broad application across diseases, and maintains the human touch needed to drive high adherence rates,” said Sebastian Seiguer, CEO of emocha. “Tom will play a key role as emocha looks to bring these product benefits to new markets in our next stage of growth. We are pleased to add him to the emocha team.”
Patients use emocha’s mobile smartphone application to video record medication ingestion, report side effects, and receive medication reminders. Healthcare providers or emocha adherence coaches can assess data collected through a secure web portal, engage with patients through the application to provide additional support, and intervene quickly in the case of medication nonadherence or reported symptoms and side effects.
“emocha brings an elegant and easy-to-use solution to the chronic problem of medication nonadherence,” said Carroll. “I am thrilled to join emocha in pursuing new opportunities to bring better care to patients while lowering costs to the healthcare system.”
emocha’s mobile video Directly Observed Therapy has been cited by the U.S. Centers for Disease Control and Prevention for its role in helping stop a tuberculosis (TB) outbreak last year in Puerto Rico and for keeping 59 of 61 patients 100 percent adherent to their TB medications in the aftermath of Hurricane Harvey in Houston. The technology is in use in more than 30 sites across 19 U.S. states and territories and 3 countries for a variety of applications including TB, hepatitis C, HIV and opioid use disorder.
emocha leverages technology licensed from Johns Hopkins University that delivers video directly observed therapy (DOT) to help people stay adherent to medication. Patients use a smartphone application to record videos of themselves taking each dose of medication and report any associated side effects. Providers assess patient data using a secure web portal and contact patients as needed. emocha works with public health departments, academic medical centers, payers and providers to secure adherence to tuberculosis, hepatitis C, HIV, and opioid use disorder treatment. Learn more at www.emocha.com.
Research reported in this publication was supported by the National Institute On Minority Health And Health Disparities of the National Institutes of Health under Award Number R43MD010521. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.